Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
6.81
-0.23 (-3.27%)
Feb 11, 2026, 3:54 PM EST - Market open
Lexeo Therapeutics Employees
Lexeo Therapeutics had 61 employees as of September 30, 2025. The number of employees decreased by 11 or -15.28% compared to the same quarter last year.
Employees
61
Change
-11
Growth
-15.28%
Revenue / Employee
n/a
Profits / Employee
-$1,720,754
Market Cap
497.04M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 61 | -11 | -15.28% |
| Jun 30, 2025 | 61 | -8 | -11.59% |
| Mar 31, 2025 | 75 | 17 | 29.31% |
| Dec 31, 2024 | 72 | 14 | 24.14% |
| Sep 30, 2024 | 72 | 14 | 24.14% |
| Jun 30, 2024 | 69 | - | - |
| Dec 31, 2023 | 58 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 353 |
| Vor Biopharma | 154 |
| Gossamer Bio | 145 |
| Lexicon Pharmaceuticals | 103 |
| Solid Biosciences | 100 |
| Keros Therapeutics | 82 |
| Verastem | 78 |
| Forte Biosciences | 16 |
LXEO News
- 6 days ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewsWire
- 15 days ago - Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics - GlobeNewsWire
- 4 weeks ago - Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript - Seeking Alpha
- 4 weeks ago - Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy - GlobeNewsWire
- 7 weeks ago - Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript - Seeking Alpha
- 2 months ago - Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum - GlobeNewsWire